ReviewNature reviews. Gastroenterology & hepatology2009
Systemic amyloidosis and the gastrointestinal tract.
Review in Nature reviews. Gastroenterology & hepatology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 2 syntheses or guidelines pooled it, 127 citations in OpenAlex.
- American Society of Hematology 2026 guidelines on diagnosis of light chain amyloidosis.Blood advances · 2026Guideline
- Mexican position paper for the diagnosis and treatment of cardiac amyloidosis.Archivos de cardiologia de Mexico · 2024Guideline
- Amyloidosis of the gastrointestinal tract: a 13-year, single-center, referral experience.Haematologica · 2013Trial
- Endoscopic and Histological Diagnosis of Gastrointestinal Amyloidosis: A Narrative Review.Cureus · 2026Review
- AL Amyloidosis Presenting With Chronic Gastrointestinal Symptoms in a Patient With Lymphoplasmacytic Lymphoma.ACG case reports journal · 2026Article
- Colovesical Fistula and Amyloidosis.Cureus · 2025Article
- Endoscopic and pathological characteristics of gastrointestinal amyloidosis: a retrospective analysis.BMC gastroenterology · 2025Article
- Idiopathic AA amyloidosis presenting with initial abdominal pain: a case report and literature review.Frontiers in medicine · 2025Article
- Gastrointestinal amyloidosis in a 50-year-old patient with miliary tuberculosis: A case report.Clinical case reports · 2024Article
- Localized Rectal Amyloidosis with Morphologic Changes from the Submucosal Tumor to the Ulcerative Lesion That Led to Hematochezia During Observation.Internal medicine (Tokyo, Japan) · 2023Article
- Peritoneal Amyloid as a Presenting Manifestation of AL Amyloid.Journal of community hospital internal medicine perspectives · 2023Article
- Persistent diarrhea with petechial rash - unusual pattern of light chain amyloidosis deposition on skin and gastrointestinal biopsies: A case report.World journal of clinical cases · 2022Article
- Article
- Thromboembolism and bleeding in systemic amyloidosis: a review.ESC heart failure · 2022Review
- A Case of Systemic AL Amyloidosis Diagnosed by Screening Colonoscopy.Case reports in gastrointestinal medicine · 2022Article
- Jejunal Wall Thickening and Ulceration in a Patient With Amyloid Light-chain (AL) Amyloidosis.Journal of the Canadian Association of Gastroenterology · 2021Article
- A Rare Case of Localized Esophageal Amyloidosis.Internal medicine (Tokyo, Japan) · 2021Article
- Gastrointestinal amyloidosis: A focused review.World journal of gastrointestinal endoscopy · 2021Review
- Gastric AA amyloidosis secondary to chronic infection presenting with hematemesis: a case report.Clinical journal of gastroenterology · 2020Article
- A case report of gastric amyloidosis due to multiple myeloma mimicking gastric cancer.BMC gastroenterology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Systemic amyloidosis is characterized by the extracellular deposition of protein in an abnormal fibrillar form. Several different types of amyloidosis exist, each defined by the identity of their respective fibril precursor protein. Among patients with systemic amyloidosis, histological involvement of the gastrointestinal tract is very common but is often subclinical. Conversely, primary diseases of the gastrointestinal tract can cause systemic amyloidosis; for example, AA amyloidosis can occur secondary to IBD. The presence and pattern of gastrointestinal symptoms varies substantially, not only between the different types of amyloidosis but also within them. Typical clinical presentations, most of which are nonspecific, include macroglossia, hemorrhage, motility disorders, disturbance of bowel habit and malabsorption. Endoscopic and radiological features are also nonspecific, with the small intestine most commonly affected. Currently, the aim of therapy for amyloidosis is to slow amyloid formation by reducing the abundance of the fibril precursor protein. No specific treatments for the gastrointestinal symptoms of systemic amyloidosis are available; however, case reports and small published series encourage nutritional support for patients with motility disorders and pharmacological agents for treatment of diarrhea. Surgical procedures should be contemplated only in an emergency setting because of the risk of decompensation of organs affected by amyloid deposition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.